Remicade drives Mitsubishi Tanabe to solid growth
This article was originally published in Scrip
Executive Summary
Japanese prescription sales at Mitsubishi Tanabe Pharma (MTP) rose by 8% to ¥96.1 billion ($1.10 billion) in the first quarter ended 30 June, led again by Remicade (infliximab).